
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Net Debt 2011-2026 | CSII
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.6 M | -68.9 M | - | -53.3 M | -95.2 M | -86.8 M | -60.6 M | -83.8 M | -124 M | -55.3 M | -18 M | -9.02 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.02 M | -124 M | -65.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.35 | - | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
78.5 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
LENSAR
LNSR
|
-13.6 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
15.2 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
802 M | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Penumbra
PEN
|
-152 M | $ 334.17 | -0.41 % | $ 13 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
-10.5 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
468 M | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
-4.85 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
-7.36 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Quanterix Corporation
QTRX
|
7.4 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
-4.79 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
63 M | $ 3.53 | -2.35 % | $ 53.7 K | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 52.07 | -0.17 % | $ 1.53 B | ||
|
Sintx Technologies
SINT
|
-898 K | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.31 | -5.76 % | $ 53.3 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Sensus Healthcare
SRTS
|
-21.6 M | $ 3.96 | -3.65 % | $ 64.7 M | ||
|
InspireMD
NSPR
|
-5.65 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
NuVasive
NUVA
|
-238 M | - | - | $ 2.07 B | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M |